Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Upregulating the Nitric Oxide Pathway To Restore Autonomic Phenotype (UNTRAP). (UNTRAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03658174
Recruitment Status : Recruiting
First Posted : September 5, 2018
Last Update Posted : September 25, 2019
Sponsor:
Collaborators:
National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK
Loughborough University
University Hospitals, Leicester
Information provided by (Responsible Party):
University of Leicester

Brief Summary:

Autonomic nervous system dysfunction is known to be associated with an increased risk of heart rhythm abnormalities and sudden cardiac death (SCD) in patients with chronic heart failure - a condition affecting millions of people worldwide. The nitric oxide pathway has been identified as being involved in mediating the effects of the autonomic nervous system on the heart. Recent studies have shown that dietary nitrates can increase the availability of nitric oxide in the body.

This study hopes to find out if dietary nitrate supplementation can help to improve cardiac and autonomic function in patients with heart failure and autonomic dysfunction and reduce the risk of arrhythmias.


Condition or disease Intervention/treatment Phase
Heart Failure Arrhythmia Dietary Supplement: Nitrate-rich beetroot juice Dietary Supplement: Nitrate-free beetroot juice Not Applicable

Detailed Description:

20 participants enrolled at the University Hospitals of Leicester NHS Trust will be invited to take a beetroot juice supplement, which naturally contains a high concentration of nitrates, and a nitrate-free (placebo) beetroot supplement. In a double blind way, participants will be randomised to the order in which they receive the 2 treatments with crossover of the treatments. There will be a washout period between the two treatments.

In order to assess cardiac and autonomic function, and risk of heart rhythm abnormalities, tests will be carried out before and after each treatment period

Hypotheses:

  • Nitrate supplementation reverses the autonomic dysfunction seen in Chronic Heart Failure (CHF)
  • Markers of prognostic significance for predicting SCD, including QT variability index and cardiac restitution properties (R2I2, PERS), are normalised by nitrate supplementation in patients with CHF.
  • Nitrate supplementation results in functional improvement in CHF patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Double blind placebo controlled crossover study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Upregulating the Nitric Oxide Pathway To Restore Autonomic Phenotype (UNTRAP). A Double Blind Randomised First "Proof of Concept" Direct Translational Study to Explore the Effects of Dietary Nitrate Supplementation on Autonomic Function in Heart Failure Patients
Actual Study Start Date : August 31, 2018
Estimated Primary Completion Date : February 21, 2020
Estimated Study Completion Date : February 21, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Active Comparator: Nitrate-rich beetroot juice
70mls of concentrated beetroot juice to be taken twice a day. This contains 5-6 mmol of inorganic nitrate.
Dietary Supplement: Nitrate-rich beetroot juice
70mls of concentrated beetroot juice containing approximately 5-6 mmol of inorganic nitrate

Placebo Comparator: Nitrate-free beetroot juice
70mls of concentrated nitrate-free beetroot juice to be taken twice a day. This is an identical juice from which the nitrate has been removed using a standard anion exchange resin.
Dietary Supplement: Nitrate-free beetroot juice
70mls of concentrated beetroot juice that has been nitrate-depleted
Other Name: placebo




Primary Outcome Measures :
  1. Change in heart rate variability (HRV) from baseline [ Time Frame: 4 weeks and 8 weeks ]
    Measure of autonomic function

  2. Change in QT variability index (QTVI) from baseline [ Time Frame: 4 weeks and 8 weeks ]
    Marker of arrhythmia risk

  3. Change in Regional Restitution Instability Index (R2I2) from baseline [ Time Frame: 4 weeks and 8 weeks ]
    Marker of ventricular arrhythmia and sudden cardiac death risk

  4. Change in Peak Electrocardiogram Restitution Slope (PERS) from baseline [ Time Frame: 4 weeks and 8 weeks ]
    Marker of ventricular arrhythmia and sudden cardiac death risk


Secondary Outcome Measures :
  1. Change in left ventricular function from baseline [ Time Frame: 4 weeks and 8 weeks ]
    LVEF, volumes and filling pressure (E/e ratio)

  2. Change in peak oxygen uptake (VO2max) on cardiopulmonary exercise test from baseline [ Time Frame: 4 weeks and 8 weeks ]
    Maximum oxygen uptake

  3. Change in total exercise time on cardiopulmonary exercise test from baseline [ Time Frame: 4 weeks and 8 weeks ]
    Time to exhaustion on exercise test

  4. Change in the total score on the Minnesota Living With Heart Failure Quality of Life Questionnaire from baseline [ Time Frame: 4 weeks and 8 weeks ]
    Measured using Minnesota Living With Heart Failure Quality of Life Questionnaire, with total score ranging from 0 to 105

  5. Participant compliance with dietary supplement [ Time Frame: 4 weeks and 8 weeks ]
    Compliance as measured using supplement and food diary

  6. Correlation between Non-Invasive Programmed Stimulation (NIPS) derived and exercise ECG derived R2I2 and PERS values [ Time Frame: 4 weeks ]
    Assessment of the correlation between R2I2 and PERS values recorded using NIPS and exercise ECG



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female.
  • Diagnosed with chronic heart failure - NYHA II-III
  • Reduced heart rate variability
  • Left ventricle ejection fraction (LVEF) of ≤40%
  • Sinus rhythm on 12 lead ECG
  • Must have an adequate understanding of written and spoken English
  • Female participants of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter
  • Able (in the Investigators opinion) and willing to comply with all study requirements

Non-Invasive Programmed Stimulation (NIPS) Sub-Study Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the study
  • Patients has a pre-existing ICD device with right ventricular apical lead

Exclusion Criteria:

  • Myocardial infarction or coronary revascularization within the last 6 months before study enrolment
  • NYHA class IV heart failure symptoms
  • Persistent Atrial Fibrillation (AF)/Atrial flutter, or paroxysmal AF with frequent recent episodes of prolonged AF
  • Patients taking any other nitrate containing medication or supplement (e.g. Isosorbide mononitrate, GTN)
  • Patients taking proton pump inhibitors
  • Severe pulmonary disease
  • Significant renal impairment (eGFR<15)
  • Active cancer with life expectancy < 1year
  • Patients with significant diabetic or other autonomic neuropathy
  • Current or recent (within the last year) cigarette smokers
  • Female participants who are pregnant, lactating or planning pregnancy during the course of the study.
  • Due to undergo any scheduled elective surgery or other procedures requiring general anaesthesia during the study.
  • Participant who is inappropriate for placebo therapy
  • Subjects who do not have an adequate understanding of written and spoken English
  • Any other significant disease or disorder, which in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • Participants who have participated in another research study involving an investigational product in the past 12 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03658174


Contacts
Layout table for location contacts
Contact: Zakariyya Vali, MBChB, MRCP +44(0)1162583643 z.vali@le.ac.uk
Contact: Andre Ng, MBChB, PhD +44(0)1162502438 andre.ng@leicester.ac.uk

Locations
Layout table for location information
United Kingdom
Glenfield Hospital, University Hospitals of Leicester NHS Trust Recruiting
Leicester, Leicestershire, United Kingdom, LE3 9QP
Contact: Zakariyya Vali, MBChB    +44(0)1162583297    z.vali@le.ac.uk   
Sponsors and Collaborators
University of Leicester
National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK
Loughborough University
University Hospitals, Leicester
Investigators
Layout table for investigator information
Principal Investigator: Andre Ng, MBChB, PhD University of Leicester

Layout table for additonal information
Responsible Party: University of Leicester
ClinicalTrials.gov Identifier: NCT03658174     History of Changes
Other Study ID Numbers: UoL 0675
Edge ID 108647 ( Other Identifier: University Hospitals of Leicester NHS Trust )
First Posted: September 5, 2018    Key Record Dates
Last Update Posted: September 25, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Leicester:
Nitrate
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters
Protective Agents